OPKO and Entera partner to develop obesity pill
OPKO partners with Entera Bio for a new obesity treatment. The once-daily pill targets obesity and related disorders.
View signal analysisCompany intelligence
OPK
OPKO Health, Inc. · NASDAQ · Healthcare
Price$1.56-0.64% · −$0.01
Market cap1.16BEquity value
P / E-5.8Trailing ratio
Volume2.04MLatest session
Market data
TradingViewOPK price chart
Related signals
1 min delayedLatest OPK price-moving signals
Browse public OPK signals with their source context and measured market impact. Open any signal for its permanent analysis page.
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
- OPKO Health reported a loss of 12 cents per share, wider than last year's 2 cents. - Revenues decreased to $173.7 million, missing estimates, especially from intellectual property transfer. - Pharmaceuticals revenue declined by 5.7% due to international sales decrease and currency fluctuations. - Gross profit declined 57.7% primarily due to the absence of upfront payments. - OPKO Health expects second-quarter revenues between $180 million and $185 million. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysisOPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
-Significant decrease in revenue and EPS for OPKO Health in Q1 2024. -Revenue from transfer of intellectual property and other decreased by 86.6% year over year. -Stock performance down 5.7% in the past month compared to the S&P 500. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysisResearch